Expert Interview
Discussing GSK's Phase II results for Linerixibat, an investigational targeted inhibitor of the ileal bile acid transporter for patients with cholestatic pruritus (relentless itch) from primary biliary cholangitis (PBC)
Ticker(s): GSKInstitution: NYU Langone Great Neck Medical
- Gastroenterologist who treats 750 patients with NASH.
- Assistant Professor of gastroenterology and hepatology at NYU Langone Health Tisch Hospital
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
